Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. Caetano
P2.01-32 Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.01-128 Low Positivity Rate in T790M Detection With ctDNA in NSCLC and Post EGFR-TKI Progression – Timing or Sensitivity?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.13-14 the Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer
Oncology Letters
Cancer Research
Oncology
P2.01-06 HSP72 Expression Associates With Survival in EGFR Mutated NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management